13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Frankfurt |
89,000 |
31.05.24 14:01:50 |
+1,000 |
+1,14% |
89,790 |
89,970 |
88,000 |
88,000 |
|
REGENERON PHARMAC.DL-,001 |
881535 |
Frankfurt |
898,400 |
31.05.24 08:14:27 |
+17,200 |
+1,95% |
893,600 |
899,200 |
898,400 |
881,200 |